FDA clears Vertex to continue dosing in diabetes cell therapy trialClinical Trials, FDA/Regulatory, R&D, TherapeuticsVertex Pharmaceuticals announced Tuesday that the U.S. Food and Drug Administration has lifted its clinical hold on the company’s Phase I/II clinical trial of VX-880, a pancreatic islet cell replacement therapy for people with Type 1 diabetes (TID). Read more July 5, 2022/by BioSpace https://www.pharmalive.com/wp-content/uploads/2021/12/Vertex-Kidney-Disease-Drug-Proves-its-Worth-in-Phase-II-BioSpace-12-1-21.jpeg 350 625 BioSpace https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png BioSpace2022-07-05 10:30:522022-07-05 13:37:43FDA clears Vertex to continue dosing in diabetes cell therapy trial